--- title: "U.S. stock market midday update: Prenetics Global down 13.65%, received $1 billion investment but faced sell-off" type: "News" locale: "en" url: "https://longbridge.com/en/news/292794694.md" description: "Prenetics Global fell 13.65%; SiVis rose 1.50%, with a transaction volume of USD 293 million; Hims & Hers Health rose 5.05%, with a transaction volume of USD 229 million; Cigna Insurance rose 0.25%, with a transaction volume of USD 108 million; Quest Diagnostics fell 0.17%, with a market value of USD 22.8 billion" datetime: "2026-07-15T16:02:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292794694.md) - [en](https://longbridge.com/en/news/292794694.md) - [zh-HK](https://longbridge.com/zh-HK/news/292794694.md) generator: "portal-rs" --- # U.S. stock market midday update: Prenetics Global down 13.65%, received $1 billion investment but faced sell-off **U.S. Stock Market Midday Update** Prenetics Global fell 13.65%. Based on recent news, 1. On July 14, Prenetics Global announced that its IM8 received $1 billion in growth financing from General Catalyst. This news was expected to boost market confidence, but the stock price dropped significantly, possibly due to investor concerns about the financing structure and future profitability. 2. On July 14, Prenetics Global raised its revenue guidance for IM8 for the full year 2026 to between $210 million and $220 million, and expects full-year revenue for 2027 to reach $400 million or more. Although this news indicates the company's future growth potential, the market reacted negatively, leading to a decline in stock price. 3. On July 14, Prenetics Global's IM8 brand achieved a 42-fold revenue growth over the past 19 months. However, the market has doubts about the sustainability of this rapid growth, putting pressure on the stock price. Macroeconomic data is strong, with exports growing by 10%. **Top Stocks by Industry Trading Volume** CVS Health rose 1.50%, with active trading. Based on recent key news: 1. On July 14, CVS Caremark reached a global agreement with the Federal Trade Commission aimed at improving the affordability of prescription drugs. This agreement resolved all outstanding issues, solidifying CVS's leadership position in the industry and driving the stock price up. 2. On July 14, Truist Securities reiterated its "Buy" rating on CVS and raised the target price from $108 to $118, reflecting market confidence in its future growth. 3. On July 13, CVS announced a dividend of $0.67 per share, enhancing investor confidence in the company's financial health, further supporting the rise in stock price. Changes in pharmaceutical industry policies are affecting market sentiment. Hims & Hers Health rose 5.05%. Based on recent news, 1. On July 15, Hims & Hers Health rose nearly 4% during trading, currently reported at $36.41. The stock price increase reflects market confidence in the company's future performance. 2. On July 14, Hims & Hers Health announced it will release its Q2 2026 financial report on August 10 and will hold a conference call after the market closes. Investors are eagerly anticipating the upcoming financial report, driving the stock price up. 3. On July 14, Hims & Hers Health collaborated with well-known brands like Peloton to participate in a social center project celebrating modern Black culture. This move enhanced the company's brand image and attracted more investor attention. The market is confident in the company's future performance, driving the stock price up Cigna Insurance rose by 0.25%. Based on recent news, 4. On July 15, Claritev announced that the Department of Justice's criminal antitrust investigation has concluded, but the company has received a civil investigation request. Claritev stated that it will fully cooperate with the Department of Justice to provide the required information. This news has had a certain impact on market sentiment. 5. On July 15, U.S. President Trump launched the TrumpRx.gov website, offering discounts on hundreds of generic and brand-name drugs, particularly popular weight loss medications. This initiative aims to reduce drug prices and has impacted the pharmaceutical industry. 6. On July 15, the FTC requested CVS to provide customers with the option to opt-out of the rebate payment model. These rebates are paid by drug manufacturers to pharmacy benefit managers and may or may not be passed on to plan sponsors or consumers after drug distribution. Significant policy changes in the pharmaceutical industry need to be monitored. **Stocks ranked at the top of the industry by market capitalization** Quest Diagnostics fell by 0.17%, with a market capitalization of $22.8 billion, and trading volume increased, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation ### Related Stocks - [PRE.US](https://longbridge.com/en/quote/PRE.US.md) - [CVS.US](https://longbridge.com/en/quote/CVS.US.md) - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [CI.US](https://longbridge.com/en/quote/CI.US.md) - [DGX.US](https://longbridge.com/en/quote/DGX.US.md) ## Related News & Research - [Prenetics Global Q2 revenue jumps on AI brand growth](https://longbridge.com/en/news/296222403.md) - [Prenetics Global (NASDAQ:PRE) Posts Earnings Results, Beats Expectations By $0.32 EPS](https://longbridge.com/en/news/296224368.md) - [Prenetics’ IM8 Brings Lily Collins On Board as Global Ambassador and Shareholder Amid Raised 2026–2027 Guidance](https://longbridge.com/en/news/296510440.md) - [Prenetics Names Veteran Wall Street Analyst Caroline Levy to Board as Independent Director](https://longbridge.com/en/news/296115464.md) - [The Relevant Practices of EU in Investigation of JD.Com Constitute Improper Extraterritorial Jurisdiction, MOJ Says](https://longbridge.com/en/news/296446232.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**